Case Study: a Fortune 500 pharma company mitigates $3B in tariff-exposed spend with GEP

Fortune 500 Pharma mitigates $3B tariff-exposed spend with GEP

A U.S. pharmaceutical company, a Fortune 500 pharma giant, faced significant risk with a large portion of its $12 billion spend exposed to potential tariffs due to a supply base in high-tariff countries. To proactively manage this tariff risk and gain clarity on potential cost escalations, the company partnered with GEP for a comprehensive diagnostic of its procurement spend.

GEP conducted a full diagnostic that identified over $3 billion of the client's spend as exposed to tariff impact. The vendor provided real-time tariff tracking via a dynamic dashboard and developed risk frameworks and heat maps to prioritize mitigation actions. This partnership enabled the Fortune 500 pharma company to develop strategies and execution roadmaps to effectively reduce its substantial tariff liability.